Related Experiment Videos
Large keratoacanthomas treated with intralesional interferon alfa-2a
J J Grob1, F Suzini, M A Richard
1Service de Dermatologie, Hôpital Ste. Marguerite, Marseille, France.
Journal of the American Academy of Dermatology
|August 1, 1993
Summary
Intralesional interferon alfa-2a (IFN alfa-2a) effectively treated giant keratoacanthomas (KAs), accelerating healing and improving cosmetic outcomes. This approach offers a promising alternative for managing KAs, minimizing scarring and mutilation.
Area of Science:
- Dermatology
- Oncology
- Virology
Background:
- Giant keratoacanthomas (KAs) can result in significant scarring and disfigurement.
- Human papillomaviruses (HPVs) have been identified as potential contributors to KA development.
- Intralesional interferon alfa-2a (IFN alfa-2a) exhibits anticancer and antiviral properties.
Purpose of the Study:
- To assess the efficacy of intralesional IFN alfa-2a in halting the progression of large KAs.
- To evaluate the potential of intralesional IFN alfa-2a to expedite the healing process of KAs.
- To determine if intralesional IFN alfa-2a can achieve favorable cosmetic results in KA treatment.
Main Methods:
- Six patients with large KAs were enrolled in the study.
- Treatment involved the administration of intralesional IFN alfa-2a directly into the lesions.
- The study monitored lesion regression, healing time, and cosmetic outcomes.
Main Results:
- Complete regression of KAs was observed in five out of six cases within 3 to 7 weeks.
- Excellent cosmetic results were achieved in the successfully treated cases.
- The primary adverse effect reported was pain experienced during the IFN alfa-2a injections.
Conclusions:
- Intralesional IFN alfa-2a demonstrates significant potential in treating giant keratoacanthomas.
- The treatment accelerates the healing of KAs and leads to improved cosmetic results.
- IFN alfa-2a may be a valuable therapeutic option for limiting scarring and preventing mutilation associated with KAs.